Navigation Links
New Treatment For Psoriasis Is Highly Effective

A new treatment for psoriasis that targets its key inflammatory mediators (IL-12 and IL-23) is highly effective//, according to a study by University of Utah researchers.

Current treatments for psoriasis include topical medicines and UV light therapy to treat the symptoms of the disease. Many of these treatments are messy, time consuming, have cumulative toxicities, and are not very effective, according to Gerald Krueger, M.D., principal investigator for the study. Krueger is a professor of dermatology and a Benning Presidential Endowed Chair at the University of Utah School of Medicine.

He says the results of the study are especially intriguing because of what it may mean for other immune mediated diseases that share the same signaling pathways, specifically inflammatory bowel disease (IBD).

In 2005 another team of researchers (Mannon et al for the anti-IL-12 Study Group) showed that a different human monoclonal antibody to p40 was effective in the treatment of IBD. 'These results suggest that therapeutics that target the IL-12 and IL-23 signaling pathway appear to effectively treat both psoriasis and IBD,' he said.

According to Krueger, the story of the link between psoriasis and IBD gains intrigue by events independent of these reports of treatment success. In October of last year the University of Utah and Celera Group of Applera Corporation reported at the American Association of Human Genetics annual meeting that psoriasis patients carry a common polymorphism in the gene for p40 (IL12B) more often than control subjects. Further exploration led to a discovery of a second polymorphism in the receptor for IL-23 that also associates with psoriasis. These results were recently published in the American Journal of Human Genetics (Cargill et al. 2007). Duerr and colleagues (2006) have reported that the same variant in the IL-23 receptor is associated with IBD. The common forms of these polymorphisms are associated wi th risk of both psoriasis and IBD, while the uncommon forms are protective, according to Krueger.

'This is really an alignment of the stars. It’s unusual that targeting a new inflammatory pathway in two different diseases provides patients with dramatic improvement,' he said. 'And then, almost simultaneously, we find disease-associated genetic variants in this same pathway.'

Krueger and colleagues at Celera predict that refinement of disease association patterns to specific genetic variants within IL-12/23 and the IL-23 receptor will play an important role in the elucidation of the causes of psoriasis, and IBD.

Krueger says that, 'Further studies should help determine whether any of the identified differential risk polymorphisms are also associated with response to therapy and possible toxicities and thereby help determine the most effective dosage of these new monoclonal antibody therapies.'

Source-Newswise
'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/20/2017)... ... February 20, 2017 , ... ... you to stop by for a visit this week at HIMSS 2017 Conference ... executives from around the globe. Sensogram will be featured in the conference’s Connected ...
(Date:2/20/2017)... ... February 20, 2017 , ... ReportingMD, a Population Health Software Company, is pleased to ... company. The new location will triple the size of the previous location while bringing ... of Sunapee, NH. , “We are excited to expand our footprint to better ...
(Date:2/20/2017)... ... February 20, 2017 , ... Johns Hopkins All Children's ... building. A topping out ceremony on Friday marked the halfway point of construction and ... open in Fall 2018, will serve as a center for innovation aimed at finding ...
(Date:2/20/2017)... ... February 20, 2017 , ... Today, Illuma Care Connections, a ... during the 2017 Annual HIMSS Conference & Exhibition in Orlando, Florida, ... and integrating eye care into mainstream healthcare delivery is powered by Secure ...
(Date:2/19/2017)... ... , ... The Citadel’s new Swain Department of Nursing , along with ... Ph.D. Joseph was engaged by the college as a consultant to help build the ... a nation-wide search, she was selected to head the department as nurse administrator, assuming ...
Breaking Medicine News(10 mins):
(Date:2/19/2017)...   AC Group Inc. , a leading company, ... in the PMS/EHR healthcare marketplace, will exhibit the 7 ... succeed in this ecosystem at HIMSS,17. ... from over 200 ACOs, compared and analyzed an ACO,s ... that are providing different pieces of Population Health technologies ...
(Date:2/18/2017)... , Feb. 17, 2017   Parker ... protecting the rights of victims injured by medical ... regulators to call for better reporting. Congress required ... Safety concerns involving power morcellators and duodenoscopes ... to investigate how hospitals report injuries and deaths ...
(Date:2/17/2017)... CINCINNATI , Feb. 17, 2017  Ethicon, ... Torax Medical, Inc., a privately held medical device ... Reflux Management System, a novel minimally invasive ... acquisition of Torax Medical will enable Ethicon to ... the anatomy-altering laparoscopic Nissen fundoplication surgical procedure. 1 ...
Breaking Medicine Technology: